ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
08 Apr, 2025
Serina Therapeutics, Inc., a clinical-stage biotechnology company leveraging its proprietary POZ Platform™ drug optimization technology, has announced the successful closing of a $5 million financing round from strategic shareholders. The proceeds will support ongoing development of SER-252 (POZ-apomorphine), the company’s lead clinical candidate for the treatment of advanced Parkinson’s disease. Serina plans to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
“This financing further strengthens our cash position and reflects the confidence of our strategic investors in the potential of SER-252,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “With a novel approach to achieving continuous dopaminergic stimulation, we believe SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson’s disease. We remain focused on initiating first-in-human studies later this year.”
As part of the financing, Serina issued 965,250 shares of convertible preferred stock at a price of $5.18 per share, equal to the closing price of its common stock on April 7, 2025.
About SER-252 (POZ-apomorphine)
SER-252 is an investigational therapy developed using Serina’s POZ platform and designed to deliver continuous dopaminergic stimulation (CDS), a strategy shown to reduce levodopa-related motor complications such as dyskinesia and to improve “on” time while reducing “off” time in patients with advanced Parkinson’s disease. The therapy incorporates the enFuse™ wearable drug delivery system from strategic partner Enable Injections, providing a long-acting subcutaneous injection that is easy to administer and does not cause skin reactions.
About the POZ Platform™
Serina’s proprietary POZ technology is built on poly(2-oxazoline), a synthetic, water-soluble, low-viscosity polymer. The platform enables precise drug loading and controlled release of therapeutics via subcutaneous injection. Serina applies the POZ platform to reformulate well-established drugs with known safety profiles, enhancing their pharmacokinetics by minimizing side effects, extending half-life, and improving stability. The platform has broad potential across various drug types and therapeutic indications.